August 3, 2006
According to NASTAD's latest ADAP Watch, released today, a total of 310 individuals were on ADAP waiting lists in five states as of July 27, 2006 (see Watch for details). Four of those five states have had ADAP waiting lists for the past 18 months. Two ADAPs were able to eliminate their waiting lists since NASTAD's June Watch due to increased state funding and rolling recertification; however, both have also capped program enrollment and plan to reinstitute those lists upon receipt of new applications.
Waiting lists are only one indication of the financial strain on ADAPs. Five ADAPs have been forced to adopt new cost-containment measures since April 1, 2006 (the beginning of the 2006 ADAP fiscal year), including capped enrollment, formulary reductions, cost sharing, and annual per capita expenditure caps. Seven other states anticipate the need to implement new or additional cost-containment measures during the current fiscal year, which ends March 31, 2007.
"Without a long-term investment in the financial stability of ADAPs, progress in reducing the number of individuals on waiting lists will undoubtedly be short-lived," warned Julie Scofield, NASTAD's Executive Director. "Passage of proposed changes to strengthen the ADAP Supplemental in a reauthorized CARE Act -- coupled with increased funding -- is essential to ensure that these programs continue to provide life-saving medications to the most vulnerable populations," she asserted.
Despite the growing demand for HIV medications as people with HIV/AIDS live longer, more productive lives, the funding outlook for ADAP is uncertain. In Congress, the House Appropriations Committee has provided a $70 million increase for Title II of the CARE Act for FY2007 but no increase for ADAPs specifically. In contrast, the Senate Committee has increased ADAP funding by $55 million and Title II base funding by $15 million. NASTAD is appreciative of the funding increases given the tight budget year but acknowledges that the need is much larger -- estimated to be $197 million more than FY2006 funding levels. In conjunction with reauthorization of the CARE ACT, NASTAD supports a $30 million increase for the Title II base and a $40 million increase for ADAP. NASTAD also urges Congress to ensure that a reauthorized CARE Act provides stable, predictable funding for ADAPs on a long-term basis.
"The CARE Act is a crucial safety net for our nation's poor and uninsured," stated Scofield. "With reauthorization, Congress has the opportunity to make waiting lists and other program restrictions obsolete and maximize access to treatment for people in need."
ADAPs provide HIV treatments to low income, uninsured, and underinsured individuals living with HIV/AIDS in all 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and one U.S. Pacific territory (Guam). Each year, approximately 135,000 individuals receive services from ADAPs, representing about 30% of those estimated to be living with HIV/AIDS and receiving care in the U.S. ADAPs are a discretionary grant program funded through the Ryan White CARE Act. Because ADAPs are not entitlement programs, funding levels are not based on the number of people requiring prescription drugs or on the cost of medications. In addition to federal funding, many ADAPs may also receive state general revenue support and other funding, but these sources are highly variable and dependent on local decisions and resource availability.